Stocktoria
Propanc Biopharma, Inc. PPCB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-06-15
Propanc Biopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $223,721 | $248,102 | $247,919 | $256,052 | $230,956 |
| Operating income | -$57.3M | -$1.5M | -$1.8M | -$2.0M | -$1.8M |
| Interest expense | — | — | $532,821 | $568,798 | $449,457 |
| Income tax | — | -$129,132 | -$129,841 | -$54,977 | -$113,415 |
| Net income | -$58.9M | -$1.8M | -$2.7M | -$2.7M | -$2.0M |
| EPS (diluted) | $-14.85 | $-1420.53 | $-1.80 | $-49.23 | — |
| Operating cash flow | -$405,168 | -$935,118 | -$1.1M | -$1.4M | -$1.1M |
| Cash & equivalents | — | — | — | $4,067 | $2,255 |
| Total assets | $19.6M | $72,365 | $60,328 | $81,651 | $13,101 |
| Total liabilities | $5.7M | $3.9M | $3.2M | $3.1M | $3.1M |
| Shareholders' equity | $13.9M | -$3.8M | -$3.1M | -$3.0M | -$3.1M |
Source: SEC EDGAR filings · CIK 0001517681 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.